https://www.tumorealpolmone.it/esmo-2017-ultimi-aggiornamenti-dal-congresso-a-madrid/ 2020-05-02T08:17:10+00:00 https://www.tumorealpolmone.it/wp-content/uploads/2020/03/tumore_polmone_ESMO-2017.jpg https://www.tumorealpolmone.it/asco-2017-aggiornamenti-dal-congresso-di-chicago/ 2020-05-02T08:17:21+00:00 https://www.tumorealpolmone.it/wp-content/uploads/2020/03/tumore_polmone_asco_2017.png https://www.tumorealpolmone.it/il-top-degli-studi-presentati-a-vienna-allultimo-congresso-mondiale-sul-tumore-polmonare/ 2020-05-02T08:17:42+00:00 https://www.tumorealpolmone.it/wp-content/uploads/2020/03/IASLC_1_ltl.jpeg https://www.tumorealpolmone.it/congresso-esmo-2016-le-ultime-novita/ 2020-05-02T08:17:49+00:00 https://www.tumorealpolmone.it/crizotinib-per-ros1/ 2021-12-15T12:03:19+00:00 https://www.tumorealpolmone.it/atezolizumab-nuova-schedula/ 2021-12-15T12:03:41+00:00 https://www.tumorealpolmone.it/pembrolizumab-nuova-schedula/ 2021-12-15T12:08:30+00:00 https://www.tumorealpolmone.it/novita-nel-mondo-dellimmunoterapia/ 2021-12-15T12:23:45+00:00 https://www.tumorealpolmone.it/wp-content/uploads/2020/03/tumore_polmone_novita_immunoterapia.jpg https://www.tumorealpolmone.it/approvato-nivolumab-tramite-ssn/ 2021-12-15T12:37:11+00:00 https://www.tumorealpolmone.it/loncologia-ai-tempi-del-covid-19/ 2021-12-15T12:40:44+00:00 https://www.tumorealpolmone.it/wp-content/uploads/2020/03/Covid-19-indicazioni-pazienti-oncologici.jpg https://www.tumorealpolmone.it/novita-per-i-pazienti-con-mutazione-del-gene-egfr/ 2021-12-15T12:46:54+00:00 https://www.tumorealpolmone.it/osimertinib-un-nuovo-importante-alleato-nella-lotta-contro-il-tumore-polmonare/ 2021-12-15T12:50:53+00:00 https://www.tumorealpolmone.it/quando-ladenocarcinoma-polmonare-si-trasforma-in-microcitoma-identificazione-di-nuovi-meccanismi-biologici/ 2021-12-15T12:52:16+00:00 https://www.tumorealpolmone.it/pembrolizumab-keytruda-il-primo-farmaco-immunoterapico-per-il-trattamento-di-prima-linea/ 2021-12-15T12:53:19+00:00 https://www.tumorealpolmone.it/osimertinib-come-cambia-la-strategia-terapeutica-nei-pazienti-con-mutazione-del-gene-egfr/ 2021-12-15T12:54:22+00:00 https://www.tumorealpolmone.it/wp-content/uploads/2020/03/Terapie-target-per-tumore-polmone.jpg https://www.tumorealpolmone.it/lospedale-a-casa-del-paziente-oncologico-al-via-il-progetto-pilota-oncohome-per-le-cure-domiciliari/ 2021-12-15T12:58:03+00:00 https://www.tumorealpolmone.it/novita-dal-congresso-asco-2022-come-cambia-la-terapia-neoadiuvante/ 2022-06-13T08:51:34+00:00 https://www.tumorealpolmone.it/lapproccio-terapeutico-nel-nsclc-localmente-avanzato-e-lo-studio-pacific/ 2024-11-06T12:12:26+00:00 https://www.tumorealpolmone.it/wp-content/uploads/2020/03/Alessandro-Morabito-Oncologo.jpg